BioStock: Abliva is ready for a pivotal year

Report this content

During 2021 Lund-based Abliva laid the ground for an eventful 2022 as it achieved significant advancements with its two candidates within the primary mitochondrial disease space. Lead candidate KL1333 is to enter a registrational phase II/III study during 2022, whilst the second candidate, NV354, has been given the go-ahead to proceed to clinical studies. During the last days of 2021 the company also announced a directed issue of convertible bonds in order to further advance KL1333 and provide bridge financing.

Read the article and interview with Abliva's CEO Ellen Donnelly at

This is a press release from BioStock - Connecting Innovation & Capital.


Documents & Links

Quick facts

BioStock: Abliva is ready for a pivotal year
Tweet this